Predict your next investment

Corporate Venture
massgeneralbrighamventures.com

See what CB Insights has to offer

Investments

9

About Mass General Brigham Ventures

Mass General Brigham Ventures is the venture arm for Mass General Brigham.

Mass General Brigham Ventures Headquarter Location

215 First St Suite 500

Cambridge, Massachusetts, 02142,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mass General Brigham Ventures News

Syncona invests in $56 million Series B financing of SwanBio Therapeutics

May 18, 2022

Syncona invests in $56 million Series B financing of SwanBio Therapeutics Syncona invests in $56 million Series B financing of SwanBio Therapeutics     Syncona invests in SwanBio’s $56 million (£45 million) Series B financing round, committing $54 million (£44 million [1] ), alongside investment from Mass General Brigham Ventures Proceeds will primarily be used to support SwanBio’s ongoing clinical development of its lead candidate, SBT101, for adrenomyeloneuropathy (AMN), which is expected to enter the clinic this calendar year Syncona’s holding value is now £96 million, following first tranche investment of $19 million (£16 million); on drawdown of the full Series B financing, Syncona's ownership stake in the business will be 80 per cent [2]     Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that it has committed $54 million (£44 million) in a $56 million (£45 million) Series B financing in SwanBio Therapeutics (“SwanBio”), a gene therapy company advancing adeno-associated vector (AAV)-based therapies for the treatment of devastating, inherited neurological conditions. Syncona led the financing round alongside Mass General Brigham Ventures. Following the drawdown of the full Series B financing, Syncona's ownership stake in SwanBio will be 80 per cent. Including the drawdown of the first tranche investment of $19 million (£16 million), Syncona’s holding value of SwanBio is now £96 million. SwanBio is a gene therapy company co-founded by Syncona in 2018 to develop medicines for serious neurological diseases with significant unmet need. Its lead candidate, SBT101, is designed to treat a rare, inherited neurodegenerative disease affecting the spine called adrenomyeloneuropathy (AMN). There are currently no approved treatments for AMN, which emerges in adulthood and is characterised by a loss of mobility, incontinence, pain and sexual dysfunction. In the US and Europe, between 8,000 and 10,000 men are living with this disease and their only option is managing its progressive and debilitating symptoms. SwanBio's gene therapy is looking to target the underlying cause of AMN - mutations of the ABCD1 gene - which lead to disrupted function of spinal cord cells and other tissues. This latest financing round follows an expanded $77 million Series A financing in 2020, taking the total amount of money raised by SwanBio in its financings to date to $133 million. The proceeds will primarily be used to support the ongoing clinical development of SBT101, which is expected to enter the clinic later this year through the initiation of a Phase I/II study. The company has a pipeline of gene therapy candidates for other neurological conditions, with a focus on spinal cord-related disorders, and is applying learnings from the development of SBT101 to develop therapies for both monogenic and polygenic disorders, conditions caused by single genes or the combined effect of many genes, respectively. Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited and Chair of SwanBio said: “Since our initial investment, SwanBio has made excellent progress, with the company rapidly advancing its lead programme for AMN towards the clinic. In parallel, the company has built the platform capabilities that will allow it to advance its broader pipeline of AAV gene therapies for spinal cord-related disorders towards clinical development. We are excited by the potential we see in this business to become a leading gene therapy company delivering life changing treatments to patients with debilitating neurological disorders.”   Tom Anderson, Chief Executive Officer and Director of SwanBio said: “We are determined in our pursuit of AAV-based therapies targeting the root cause of disease, and are building our pipeline to develop treatments where there is a significant unmet need. The strategic decisions we make as a company are motivated by our drive to help those affected by neurological diseases as soon as possible because they can’t wait – and we don’t want them to.” [1] FX rates at 17 May 2022. Includes previously invested convertible loan of $24 million plus accrued interest [2] Percentage holding reflects Syncona's ownership stake at the point full current commitments are invested on a fully-diluted basis Editor Details

Mass General Brigham Ventures Investments

9 Investments

Mass General Brigham Ventures has made 9 investments. Their latest investment was in SwanBio Therapeutics as part of their Series B on May 5, 2022.

CBI Logo

Mass General Brigham Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/18/2022

Series B

SwanBio Therapeutics

$56M

Yes

3

1/13/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/23/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/16/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/18/2022

1/13/2022

9/23/2021

9/16/2021

9/14/2021

Round

Series B

Series B

Series A

Series B

Series B

Company

SwanBio Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$56M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

10

Mass General Brigham Ventures Team

1 Team Member

Mass General Brigham Ventures has 1 team member, including current Managing Partner, Roger Kitterman.

Name

Work History

Title

Status

Roger Kitterman

Mi3 Venture Capital, Lee Munder, Boston University Technology Development, and Partners Innovation Fund

Managing Partner

Current

Name

Roger Kitterman

Work History

Mi3 Venture Capital, Lee Munder, Boston University Technology Development, and Partners Innovation Fund

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.